レジェネロン株の目標額は JPモルガンによって下げられた. Regeneron's stock target was lowered by JPMorgan, despite the company beating Q4 earnings estimates.

レジェネロン製薬 (NASDAQ: REGN) は,JPモルガンが価格目標を1,100ドルから1,000ドルに下げ,過重評価を維持した. Regeneron Pharmaceuticals (NASDAQ: REGN) saw JPMorgan lower its price target from $1,100 to $1,000, while maintaining an overweight rating. 同社は,第4四半期のEPSを12.07ドルと報告し,推定値を0.86ドル上回った. The company reported a Q4 EPS of $12.07, beating estimates by $0.86. 市場総額は683億9000万ドル,EYLEA注射で知られているレジェネロン (PE比率16.34) は,コンセンサス目標価格966.88ドルと平均評価"中等購入"を持っています. With a market cap of $68.39 billion and a PE ratio of 16.34, Regeneron, known for its EYLEA injection, has a consensus target price of $966.88 and an average rating of "Moderate Buy." Leerink Partnersは最近,Q1 EPSの評価を7.07に下げたが,"Stong-buy"の評価を保った. Leerink Partnrs recently lowered its Q1 EPS estimate to $7.07 but kept a "Strong-Buy" rating.